Fate Therapeutics
FATE
250 hedge funds and large institutions have $3.92B invested in Fate Therapeutics in 2022 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 101 increasing their positions, 72 reducing their positions, and 34 closing their positions.
68% more call options, than puts
Call options by funds: $9.7M | Put options by funds: $5.77M
40% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 72
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
3.47% more ownership
Funds ownership: 101.46% → 104.93% (+3.5%)
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
0% more funds holding
Funds holding: 250 → 250 (0)
31% less capital invested
Capital invested by funds: $5.66B → $3.92B (-$1.74B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$61.3M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$50.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$29.2M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$28.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$28.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.1M |
| 3 |
Morgan Stanley
New York
|
-$15.5M |
| 4 |
SG Americas Securities
New York
|
-$12.2M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$8.98M |
FATE Hedge Fund Activity: Q1 2022 in Review
250 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2022, worth a combined $3.92B — down 31% from $5.66B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new FATE positions and 34 closed out — a net gain of 2 holders — while 101 added to existing stakes and 72 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $61.3M. The largest seller was Farallon Capital Management, cutting an estimated $28.1M.
- 250 institutional investors held Fate Therapeutics (FATE) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $3.92B of Fate Therapeutics stock for Q1 2022, down 31% quarter-over-quarter.
- 36 funds opened new Fate Therapeutics positions in Q1 2022 and 34 closed out, a net change of +2 holders.
- The largest Fate Therapeutics buyer in Q1 2022 was Deep Track Capital, an estimated $61.3M added.
- The largest Fate Therapeutics seller in Q1 2022 was Farallon Capital Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q1 2022.